Table 2.

Pooled median PFS with 95% accuracy intervals for patients with EGFR mutation-positive tumours

Treatment	Number of studies	Pooled number of patients	Pooled median PFS	Accuracy interval	Bootstrap estimated 95% confidence limits
Any line of therapy
Single-agent erlotinib	26	731	12.4	11.6–13.4	10.9–13.4
Single-agent gefitinib	54	1802	9.4	9.0–9.8	8.7–10.2
Chemotherapy	20	984	5.6	5.3–6.0	5.1–6.2
Predominantly first line*
Single-agent erlotinib	10	354	12.0	10.8–13.3	10.8–13.1
Single-agent gefitinib	16	703	9.8	9.1–10.5	9.0–10.6
Chemotherapy	17	868	5.8	5.5–6.2	5.4–6.4
Lines of therapy other than first
Single-agent erlotinib	17	377	12.9	11.6–14.3	10.0–13.9
Single-agent gefitinib	37	1099	9.2	8.6–9.7	8.3–10.5
Chemotherapy	3	116	4.1	3.5–5.0	n/a†

^*Predominantly first line is ≥90% of patients treated in the first-line setting.

^†Because of the low number of studies in this pool the bootstrap estimate is not trustworthy.